Lipoxygenase pathways in atherogenesis

被引:176
作者
Zhao, L
Funk, CD
机构
[1] Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/j.tcm.2004.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
15-lipoxygeiiase-1 (also known as 12/15-LO in mice) and 5-LO/5-LO-activating protein (FLAP) cascades play central roles in low-density lipoprotein oxidation and leukotriene biosynthesis, respectively. Several genetic and expression studies unraveling an association of the 5-LO/ FLAP pathway to human cardiovascular disease have surfaced recently. Experimental studies in 12/15-LO knockout, 15-LO-1 transgenic, and 5-LO knockout mice on atherosclerotic backgrounds combined with gene expression data in human coronary artery disease have created compelling links that these pathways participate in the etiologic progression. However, a few conflicting studies and several unexplained mechanistic issues need to be resolved prior to assigning firm roles for LOs in cardiovascular disease. Development of novel pharmacologic tools to dissect the individual enzymes and receptors in the LO pathways should improve understanding of the individual components in the inflammatory aspects of atherosclerosis disease progression. (C) 2004, Elsevier Inc.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 41 条
[1]   Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice [J].
Aiello, RJ ;
Bourassa, PA ;
Lindsey, S ;
Weng, WF ;
Freeman, A ;
Showell, HJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (03) :443-449
[2]   A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit [J].
Bocan, TMA ;
Rosebury, WS ;
Mueller, SB ;
Kuchera, S ;
Welch, K ;
Daugherty, A ;
Cornicelli, JA .
ATHEROSCLEROSIS, 1998, 136 (02) :203-216
[3]  
CHEN WS, 1995, ONCOL REP, V2, P5
[4]  
Cipollone F, 2003, CIRCULATION, V108, P223
[5]  
Cornicelli JA, 1999, CURR PHARM DESIGN, V5, P11
[6]   Rupture of the atherosclerotic plaque -: Does a good animal model exist? [J].
Cullen, P ;
Baetta, R ;
Bellosta, S ;
Bernini, F ;
Chinetti, G ;
Cignarella, A ;
von Eckardstein, A ;
Exley, A ;
Goddard, M ;
Hofker, M ;
Hurt-Camejo, E ;
Kanters, E ;
Kovanen, P ;
Lorkowski, S ;
McPheat, W ;
Pentikäinen, M ;
Rauterberg, J ;
Ritchie, A ;
Staels, B ;
Weitkamp, B ;
de Winther, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (04) :535-542
[7]   Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice [J].
Cyrus, T ;
Witztum, JL ;
Rader, DJ ;
Tangirala, R ;
Fazio, S ;
Linton, MF ;
Funk, CD .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (11) :1597-1604
[8]  
Cyrus T, 2001, CIRCULATION, V103, P2277
[9]   From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation [J].
De Caterina, R ;
Zampolli, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (01) :4-7
[10]   Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].
Drazen, JM ;
Yandava, CN ;
Dubé, L ;
Szczerback, N ;
Hippensteel, R ;
Pillari, A ;
Israel, E ;
Schork, N ;
Silverman, ES ;
Katz, DA ;
Drajesk, J .
NATURE GENETICS, 1999, 22 (02) :168-170